$10.00 -0.19 (%) Dyax Corp - NASDAQ

Oct. 22, 2014 | 04:00 PM

Partner Headlines

  1. Dyax Offers Highlights of Recent Progress in Licensing, Funded-Research Portfolio

    Benzinga | Sep. 22, 2014 | 07:17AM EST
  2. FuelCell Upgrade; Amazon Announces New Product

    Benzinga | Aug. 13, 2014 | 15:28PM EST
  3. SeaWorld Drops On Downbeat Results; Canadian Solar Shares Surge

    Benzinga | Aug. 13, 2014 | 12:49PM EST
  4. Mid-Morning Market Update: Markets Gain; McDonald's Posts Lower Profit

    Benzinga | Apr. 22, 2014 | 10:46AM EST
  5. Morning Market Movers

    Benzinga | Apr. 22, 2014 | 09:43AM EST
  6. Dyax Receives FDA Approval to Expand Use of KALBITOR® (ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema to Patients 12 Years of Age and Older

    Benzinga | Apr. 3, 2014 | 16:12PM EST
  7. Mid-Day Market Update: Ulta Salon Jumps After Strong Earnings Report; Aeropostale Shares Fall

    Benzinga | Mar. 14, 2014 | 12:09PM EST
  8. Mid-Morning Market Update: Markets Mixed; Ann To Lower Around 100 Jobs

    Benzinga | Mar. 14, 2014 | 10:19AM EST
  9. Earnings Scheduled For February 28, 2014

    Benzinga | Feb. 28, 2014 | 04:58AM EST
  10. Mornings Movers for Feb. 27, 2014: PEIX, JCP, SYMX, CIE, SHLD, BBY Higher, INO, NDLS, HK, CY, DYAX Lower

    Benzinga | Feb. 27, 2014 | 09:43AM EST
  11. Benzinga's Top #PreMarket Gainers

    Benzinga | Feb. 26, 2014 | 08:13AM EST
  12. Lilly Drug Ramucirumab Boosts Lung Cancer Survival

    IBD | Feb. 19, 2014 | 11:02AM EST
  13. Dyax Announces Positive DX-2930 and Biomarker Assay Data at ASH

    Benzinga | Dec. 9, 2013 | 07:18AM EST
  14. Dyax Receives FDA Orphan Drug Designation for DX-2930 in Hereditary Angioedema

    Benzinga | Dec. 5, 2013 | 08:03AM EST
  15. Stocks Hitting 52-Week Highs

    Benzinga | Dec. 2, 2013 | 10:33AM EST
  16. Benzinga Weekly Preview: PMI Data In Focus

    Benzinga | Nov. 15, 2013 | 16:59PM EST
  17. Dyax Announces Proposed Public Offering of Common Stock

    Benzinga | Oct. 8, 2013 | 16:02PM EST
  18. Dyax Reports Dosing of First Subject in Phase 1 Trial of DX-2930

    Benzinga | Aug. 15, 2013 | 07:39AM EST
  19. Dyax Corp. Reports Operating Results (10-Q)

    GuruFocus | Oct. 29, 2012 | 13:05PM EST
  20. Stocks Hitting 52-Week Highs

    Benzinga | Oct. 16, 2012 | 04:23AM EST
  21. Dyax Corp. Creates COO Position and Expands Executive Roles

    Benzinga | Aug. 20, 2012 | 01:14AM EST
  22. Dyax Corp. Reports Operating Results (10-Q)

    GuruFocus | Aug. 2, 2012 | 16:24PM EST
  23. Merck &, Quest Diagnostics Among Stocks Setting 52-Week Highs Thursday

    FoxBusiness | Jul. 12, 2012 | 06:48AM EST
  24. Dyax Reports Results of Interim Analysis of Phase 2 Trial of Ecallantide for Acute Treatment of ACE Inhibitor-Induced Angioedema

    Benzinga | Jun. 14, 2012 | 10:04AM EST
Trading Center